[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334783-105":59,"doc-detail-334783-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumor-dna-from-discovery-to-clinical-application-in-breast-cancer","Circulating tumor DNA - from discovery to clinical application in breast cancer","","Circulating tumor DNA (ctDNA) is released from tumor cells and is positioned as a key biomarker for breast cancer research and clinical decision-making. This review explains ctDNA’s roles across screening, diagnosis, prognosis, treatment response assessment, and post-treatment follow-up, including early cancer detection, monitoring minimal residual disease, tracking early recurrence, and predicting outcomes. It also discusses how ctDNA-based strategies address limitations of conventional screening and monitoring by enabling more timely, potentially guidance-oriented information for patient management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-dna-from-discovery-to-clinical-application-in-breast-cancer/334783/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-from-discovery-to-clinical-application-in-breast-cancer/334783.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is circulating tumor DNA (ctDNA) and why is it important in breast cancer?","Question",{"text":112,"@type":113},"ctDNA originates from the release of tumor cells. It provides information for key clinical purposes such as early detection, disease monitoring, and outcome prediction in breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical applications does the review cover for ctDNA?",{"text":117,"@type":113},"The review summarizes ctDNA use for screening, diagnosis, prognosis, treatment-related monitoring, and follow-up, including minimal residual disease and early recurrence monitoring.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ctDNA-based monitoring address limitations of traditional screening methods?",{"text":121,"@type":113},"Traditional screening and monitoring may not deliver real-time information or prospective guidance. ctDNA-based approaches aim to better compensate for these shortcomings by offering more timely biomarker insights.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334783,1790153360,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 30 April 2024  \nDOI 10.3389/fimmu.2024.1355887  \nOPEN ACCESS  \nEDITED BY Zhe Wang,  \nAir Force Medical University, China  \nREVIEWED BY  \nWenzheng Guo,  \nUniversity of Kentucky, United States Xinpei Deng,  \nSun Yat-sen University Cancer Center (SYSUCC), China  \n*CORRESPONDENCE Wenjun Yi  \n [yiwenjun@csu.edu.cn](yiwenjun@csu.edu.cn)[ ](yiwenjun@csu.edu.cn)Qian Long  \n [dr_longqian@csu.edu.cn](dr_longqian@csu.edu.cn)[ ](dr_longqian@csu.edu.cn)Shirong Ding  \n [dingsr@csu.edu.cn](dingsr@csu.edu.cn)  \nRECEIVED 14 December 2023  \nACCEPTED 16 April 2024  \nPUBLISHED 30 April 2024  \nCITATION  \nXu J, Gao H, Guan X, Meng J, Ding S, Long Q and Yi W (2024) Circulating tumor  \nDNA: from discovery to clinical application in breast cancer.  \nFront. Immunol. 15:1355887 .  \ndoi: 10.3389/fimmu.2024.1355887  \nCOPYRIGHT  \n© 2024 Xu, Gao, Guan, Meng, Ding, Long and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCirculating tumor DNA: from discovery to clinical application in breast cancer  \nJiachi Xu 1,2, Hongyu Gao 1,2, Xinyu Guan 1,2, Jiahao Meng 1,2, Shirong Ding 3*, Qian Long 1,2* and Wenjun Yi 1,2*  \n1 Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China, 2Clinical Research Center For Breast Disease In Hunan Province, Changsha, China, 3 Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China  \nBreast cancer (BC) stands out as the cancer with the highest incidence of morbidity and mortality among women worldwide, and its incidence rate is currently trending upwards. Improving the efﬁciency of breast cancer diagnosis and treatment is crucial, as it can effectively reduce the disease burden. Circulating tumor DNA (ctDNA) originates from the release of tumor cells and plays a pivotal role in the occurrence, development, and metastasis of breast cancer. In recent years, the widespread application of high-throughput analytical technology has made ctDNA a promising biomarker for early cancer detection, monitoring minimal residual disease, early recurrence monitoring, and predicting treatment outcomes. ctDNA-based approaches can effectively compensate for the shortcomings of traditional screening and monitoring methods, which fail to provide real-time information and prospective guidance for breast cancer diagnosis and treatment. This review summarizes the applications of ctDNA in various aspects of breast cancer, including screening, diagnosis, prognosis, treatment, and follow-up. It highlights the current research status in this ﬁeld and emphasizes the potential for future large-scale clinical applications of ctDNA-based approaches.  \nKEYWORDS  \nbreast cancer, circulating tumor DNA, screening, diagnosis, prognosis, treatment  \nAbbreviations: AI, aromatase inhibitors; BC, breast cancer; BCLM, breast cancer leptomeningeal metastasis; cfDNA, cell free DNA; CA 15.3, carbohydrate antigen 15.3; CEA, carcinoembryonic antigen; CM, cumulative methylation; CMI, cumulative methylation index; CNAs, copy number alterations; CNVs, copy number variations; CSF, cerebrospinal ﬂuid; CT, computed tomography; ctDNA, circulating tumor DNA; DDFS, distant disease-free survival; DFS, disease-free survival; DI, DNA integrity; EGFR, epidermal growth factor receptor; ER, Estrogen receptor; HR, hormone receptor; ITH, intra-tumor heterogeneity; LOH, loss of heterozygosity; MBC, metastatic breast cancer; MRD, minimal residual disease; MSI, microsatellite instability; NAC, neoadjuvant chemotherapy; NAT, neoadjuvant therapy; NIPT, noninvasive prenatal tes","cbCaiiDcSMNN70rF","https://ap.wps.com/l/cbCaiiDcSMNN70rF","pdf",3912707,15,"English","# Introduction\n## ctDNA as a biomarker in breast cancer\n## Need for improved screening and diagnosis\n# Traditional screening and its limitations\n## Imaging-based approaches","[{\"question\":\"What is circulating tumor DNA (ctDNA) and why is it important in breast cancer?\",\"answer\":\"ctDNA originates from the release of tumor cells. It provides information for key clinical purposes such as early detection, disease monitoring, and outcome prediction in breast cancer.\"},{\"question\":\"Which clinical applications does the review cover for ctDNA?\",\"answer\":\"The review summarizes ctDNA use for screening, diagnosis, prognosis, treatment-related monitoring, and follow-up, including minimal residual disease and early recurrence monitoring.\"},{\"question\":\"How does ctDNA-based monitoring address limitations of traditional screening methods?\",\"answer\":\"Traditional screening and monitoring may not deliver real-time information or prospective guidance. ctDNA-based approaches aim to better compensate for these shortcomings by offering more timely biomarker insights.\"}]","Circulating tumor DNA - from discovery to clinical application in breast cancer | PDF",1790008368,38]